相关实验视频
Updated: Jul 5, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
托法西替尼:对反复性多态光喷发的治疗选择及其机制的合理性
Kabir Sardana1, Sinu Rose Mathachan2, Ananta Khurana1
1From the Department of Dermatology, Venereology and Leprosy, ABVIMS and Dr. Ram Manohar Lohia Hospital, New Delhi, India.
Dermatitis : contact, atopic, occupational, drug
|January 24, 2024
概括
托法西替尼有效治疗耐火多态光喷发 (PMLE),一种IV型过敏反应. 这种 Janus 激酶抑制剂迅速减轻了症状,并且在大多数患者中实现了临床缓解,即使是那些对其他治疗有耐药性的患者.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多态光喷发 (PMLE) 是对紫外线诱导的皮肤抗原的IV型过敏反应.
- 耐火性PMLE病例往往无法对传统的全身治疗和光保护做出反应.
研究的目的:
- 为了评估托法西提尼布在耐火多态光喷发患者的疗效.
- 评估Janus激酶抑制在治疗严重PMLE中的安全性和有效性.
主要方法:
- 在提供知情同意后,招募了7名耐治疗PMLE患者.
- 托法西提尼布 (tofacitinib) 被给予,并对结果进行了监测,包括减少,临床解决和复发率.
主要成果:
- 托法西提尼布的开始导致快速减少 (平均3.1天) 和临床解决 (平均2.6周).
- 在7名患者中,有4人经历了5.5周后的复发,但在重新开始托法西提尼布时迅速反应.
- 治疗持续时间从1到3个月不等.
结论:
- 托法西替尼在控制耐火多态光喷发方面表现出显著的有效性.
- 通过抑制Janus激酶 (JAK) 1和JAK3,托法西提尼布调节了PMLE中的细胞因子环境和T淋巴细胞反应.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127

